Bruker Corporation declined due to uncertainties over NIH funding and tariffs

From Yahoo Finance: 2025-05-13 11:48:00

The London Company released its first quarter 2025 investor letter, reporting a 4.3% decline in the portfolio compared to a 3.4% drop for the Russell Midcap Index. Bruker Corporation (NASDAQ:BRKR) was highlighted in the letter, with a one-month return of 2.26% and shares closing at $40.26 on May 12, 2025.

In the Q1 2025 investor letter, The London Company discussed Bruker Corporation (NASDAQ:BRKR), noting CEO share purchases amid uncertainties over NIH funding and tariffs. The company remains optimistic about BRKR’s role in life sciences research and its competitive position, innovative products, strategic capital allocation, and capable leadership.

Bruker Corporation (NASDAQ:BRKR) is not among the 30 most popular stocks among hedge funds, with 34 hedge fund portfolios holding the stock at the end of the fourth quarter. While acknowledging BRKR’s potential, the focus remains on AI stocks for higher returns. Another article covered Michael Burry stocks with significant upside potential, including BRKR.



Read more at Yahoo Finance: Bruker Corporation (BRKR) Declined Amid NIH Funding and Tariff Uncertainty